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Abstract:  Ebola virus (EBOV), a filovirus family member, is a highly pathogenic virus that causes 
Ebola hemorrhagic fever (EHF) resulting in documented mortality rates in humans as high as 50%. 
Currently, the basic EBOV virus-like particle (VLP) vaccine contains the Ebola virus (EBOV) matrix 
VP40 and attachment glycoprotein (GP). VLPs are morphologically and biochemically similar to 
parental virus, yet because they lack a genome and cannot replicate, are safe enough to be used as 
vaccines. We hypothesize that addition of a constitutionally active retinoic acid-inducible gene 1 
(RIG-I) would enhance the ability of the vaccine to induce interferon-dependent immune functions 
yielding an improved vaccine. Expression of EBOV VP40 in 293T cells induces the spontaneous 
production of VLPs into the media supernatant and if expressed with EBOV GP, will produce VLPs 
studded with the attachment GP. Recombinant chimeric constitutively active (ca)RIG-I-VP40 matrix 
and a nonfunctional mutant L58A (mu)RIG-I-VP40 matrix genes were constructed to produce VLPs 
containing constitutively active and nonfunctional RIG-I. Supernatant from 293Ts transfected with 
caRIG-I-VP40, muRIG-I-VP40 or VP40 along with GP expression plasmids were tested for the 
presence of VLPs. Western blotting of purified VLPs confirmed the presence of RIG-I in caRIG-I-
VP40 and muRIG-I-VP40, but not VP40 containing VLPs. Monocyte-like and PMA-differentiated 
macrophage-like THP-1 Dual cells were treated with nothing, VP40+GP, caRIG-I-VP40+GP, 
muRIG-I-VP40+GP VLPs as well as LPS and a Vaccinia virus (VACV-70) positive controls and 
tested for induction of interferon (IFN) signaling. CaRIG-I containing, but not muRIG-I containing 
VLPs induced interferon signaling from both macrophages and monocytes. The addition of RIG-I to 
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Ebola virus (EBOV), a filovirus family member, is a highly pathogenic virus that causes Ebola 
hemorrhagic fever (EHF) resulting in documented mortality rates in humans as high as 50%. 
Currently, the basic EBOV virus-like particle (VLP) vaccine contains the Ebola virus (EBOV) 
matrix VP40 and attachment glycoprotein (GP). VLPs are morphologically and biochemically 
similar to parental virus, yet because they lack a genome and cannot replicate, are safe enough to 
be used as vaccines. We hypothesize that addition of a constitutionally active retinoic acid-
inducible gene 1 (RIG-I) would enhance the ability of the vaccine to induce interferon-dependent 
immune functions yielding an improved vaccine. Expression of EBOV VP40 in 293T cells 
induces the spontaneous production of VLPs into the media supernatant and if expressed with 
EBOV GP, will produce VLPs studded with the attachment GP. Recombinant chimeric 
constitutively active (ca)RIG-I-VP40 matrix and a nonfunctional mutant L58A (mu)RIG-I-VP40 
matrix genes were constructed to produce VLPs containing constitutively active and 
nonfunctional RIG-I. Supernatant from 293Ts transfected with caRIG-I-VP40, muRIG-I-VP40 
or VP40 along with GP expression plasmids were tested for the presence of VLPs. Western 
blotting of purified VLPs confirmed the presence of RIG-I in caRIG-I-VP40 and muRIG-I-
VP40, but not VP40 containing VLPs. Monocyte-like and PMA-differentiated macrophage-like 
THP-1 Dual cells were treated with nothing, VP40+GP, caRIG-I-VP40+GP, muRIG-I-VP40+GP 
VLPs as well as LPS and a Vaccinia virus (VACV-70) positive controls and tested for induction 
of interferon (IFN) signaling. CaRIG-I containing, but not muRIG-I containing VLPs induced 
interferon signaling from both macrophages and monocytes. The addition of RIG-I to EBOV 
VLPs revealed an increase of interferon in human peripheral blood monocytes. 
  
Background 
The Ebolavirus (EBOV) is a deadly virus that is a member of the Filoviridae family.  
Four species of EBOV have been shown to infect and harm humans: Zaire, Sudan, Cote-d’Ivoire, 
and Bundibugyo.1 The virus can be spread through direct contact from infected to uninfected 
individuals, by the handling of contaminated fomites and by the handling of infected dead; 
EBOV can survive several hours outside of the body and can persist for days after death in 
infected individuals.2 Infected EBOV patients may experience hemorrhagic fever that leads to 
death in up to 90% of documented cases from some outbreaks.3 
The last three outbreaks of the EBOV have occurred in the last decade (2018, 2017 and 
2014), all taking place in West African countries.4 The outbreak in 2014 spanned six 6 countries 
totaling 28,600 cases and 11,300 deaths.4 Since then, research conducted on EBOV vaccines, 
pathogenesis and therapeutics has increased, however, there is no FDA-approved therapeutic or 
vaccine for this disease. The most tested EBOV vaccine is based on recombinant Vesicular 
Stomatitis Virus (VSV-GP) vector.5  
The VSV-GP recombinant vector vaccine expresses an EBOV protein (in this case 
glycoprotein (GP) from EBOV) from the vesicular stomatitis virus, which can infrequently cause 
mild disease in humans.6 While this vaccine creates epitopes for immune recognition against one 
antigen (GP), a better vaccine would contain multiple antigens. An epitope is the specific region 
on a protein antigen that antibodies recognize as foreign, which leads to an immune response. In 
the past two decades, viral-like particles have shown promising results as vaccines. Viral-like 
particles may contain proteins that come from the viral matrix of the virus itself. By using 
multiple viral proteins in a vaccine such as a virus-like particle (VLP) a better immune response 
may be initiated.7  
VLP-based vaccines have been shown to be effective and have several advantages as 
compared to other vaccine types. First, VLP-based vaccines are safer to use (and produce) than 
attenuated vaccines. While there is a risk of producing revertants when using attenuated 
vaccines, viral-like proteins-based vaccines are made with an incomplete or no viral genome and 
therefore cannot replicate to cause disease. In a study with mice, Warfield et. al. showed that 
VLP-based vaccines were 80-100% effective in protecting mice from mouse-adapted EBOV 
infection when injected 1-3 days before exposure. VLPs injected into mice also induced high 
levels of cytokine secretion and immune cells.8 Antibodies produced from VLP-based vaccines 
have a higher specificity than antibodies produced from other vaccines due to the multiple viral 
proteins present.9 A vaccine is necessary for EBOV because of its high level of virulence. 
Part of the effectiveness of EBOV is due to its strategy of disrupting the normal immune 
response. EBOV, a single-stranded, negative sense RNA virus targets antigen presenting cells 
(APC), whose functions are essential in stimulating both the innate and adaptive immune 
response. APCs are white blood cells (dendritic cells, monocytes, etc.) that continuously monitor 
for foreign invaders and eliminate cellular waste from the body. A specific APC, dendritic cells 
(DC), are infected and deregulated by EBOV. DCs and other APCs express receptors that 
recognize, bind and in some cases internalize potentially harmful antigens. Under normal 
circumstances, the internalized virus or antigen is broken apart into nonharmful peptides. Surface 
and internal pattern recognition receptors recognize pathogen antigenic patterns which stimulate 
the release of cytokines (such as interferon) and the maturation of the DC. The mature DC then 
brings the antigen to lymphoid tissues where it is presented to T cells. This process activates the 
adaptive immune response to efficiently remove that foreign invader. In general, viruses counter 
the activation of the APCs using several different mechanisms to inhibit being detected by the 
immune system. Two important mechanisms are cytokine downregulation and inhibition of 
interferon signaling.4  
It is important to understand the structure of EBOV and the function of the EBOV VP24 
and VP35 proteins to acknowledge how EBOV downregulates cytokine and interferon signaling. 
The EBOV is a filamentous virus that contains 7 structural proteins that partake in the virus’ 
activity in DC. First, entry into the DC is due to the glycoprotein (GP). GP are spike projections 
that span the enveloped membrane of the virus. It has been shown in previous studies that GP is 
essential for host cell entry, host tropism and plays a role in viral budding.3,10 This means GP is 
required for infection and spread of EBOV from host cell to another uninfected cell. Another 
structural protein of the EBOV is viral-protein 40 (VP40), which can be found on the inside of 
the viral envelope.10 VP40 is an essential protein in EBOV that functions in assembly of the 
virus and budding of the filamentous virus. The assembly and budding of EBOV is an important 
part of the spread of the virus from cell to cell.4,10 VP40 has also been shown to cause immune 
cell death, especially in T cells.4 Filamentous VLPs can be produced by expressing GP and VP40 
from 293T cells, resulting in the production of stringy VLPs containing GP spike on the VLP 
surface membrane.10 Two other EBOV proteins, VP35 and VP24, have been shown to block and 
inhibit the retinoic acid-inducible gene I (RIG-I).11 Because VLPs may not always stimulate an 
immune response efficiently, an adjuvant, RIG-I, will be added to improve the effectiveness of 
the VLP vaccine.  
We hypothesize that a VLP-based vaccine made with GP and a chimeric protein 
consisting of a constitutively active RIG-I and VP40 will more efficiently and safely stimulate 
the immune system to prevent EBOV infection. Retinoic acid-inducible gene I (RIG-I), localized 
in the cytoplasm of the host cells, is a pattern recognition receptor (PRR) specialized in detecting 
viral RNA (double stranded RNA and single stranded RNA). Type I interferon (IFN) is produced 
upon detection of viral RNA by RIG-I. IFN is a secreted signaling protein that enhances both the 
innate and adaptive immune response. We will quantify the effectiveness of adding RIG-I to 
Ebola VLPs by measuring the levels of IFN produced from monocytes stimulated by 6 different 
VLPs: (1) VP40 + RIG-I-wildtype + GP, (2) VP40 + mutant-RIG-I + GP, (3) VP40 + RIG-I-
wildtype + GPF88A, (4) VP40 + RIG-I-wildtype + GPF88A, (5) VP40 + flagVP40 + GP, and 
(6) VP40 + VSV-g.12 EBOV has been shown to interfere with the RIG-I pathway resulting in a 
decrease of interferon.13 Human cells infected with modified EBOV VLPs will transduce an 
adjuvant RIG-I to observe whether the addition of RIG-I enhances the immune response or not. 
The goal of adding RIG-I to the potential VLP vaccine is to better support immune response 
through an to increased activity of RIG-I and increase IFN concentrations.  
The goal of this experiment is to measure the amount of luminescence using a cell 
reporter assay equivalent to interferon-containing supernatant produced from human monocytes 




























Table 1. Mass of DNA (ug) added to each plasmid preparation.  
Plasmid VP40 RIGI-Wt RIGI M2-1 EBOV 
GP 
GP F88A Flag VP40 VSV-g 
1 4 12  4    
2 4  12 4    
3 4 12   4   
4 4 12   4   
5 4   4  12  
6 10      10 
 
Table 2. Volumes (uL) of solutions added to 10 cm plates 
P. CaCl2 Sterile H20 HBS 
1 144 427 600 
2 144 425 600 
3 144 415 600 
4 144 415 600 
5 144 423 600 
6 144 418 600 
 
Table 3. Volumes (uL) of VLPs and controls during monocyte stimulation representing 
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Human embryonic kidney 293t cells (HEK-293t) were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) with 10% fetal bovine serum. In a sterile hood, cells were washed with ~5 mL 
of phosphate buffer saline (PBS). After adding PBS, it was quickly aspirated, and ~2 mL of 
trypsin EDTA was added to each flask then incubated for ~3 minutes at 37 0C.  To halt trypsin 
activity, ~5 mL of DMEM containing FBS was added to cells. Cells were pipetted up and down 
repeatedly until no clumps were seen in solution. All cells were harvested and centrifuged for 10 
minutes at 1250 rpm. The supernatant was removed, and the cells were re-suspended in 25 mL of 
DMEM.  
Calcium phosphate Transfections  
Bacterial-amplified DNA was harvested using MaxiPrep kits (QIAGEN, Germantown, MD), and 
175 uL of DNA (VP40 with B-lactamase, RIG-I wild type-VP40 chimera, RIG-I mutant2-1-
VP40, EBOV GP, GP F88A, Flag VP40, VSV-g) were transferred to sterile tubes and micro-
centrifuged for 2 minutes at 13,000 rpm. After centrifuging 150 uL of the supernatant was 
removed and placed in new sterile tubes. Twelve 15 mL centrifuge tubes were separated into 2 
groups: A and B. Tube A was prepared with 2 M CaCl2, sterile water, and DNA (Table 1). Tube 
B was prepared with 600 uL 2X Hepes Buffered Saline (HBS). Solution A was then added 
dropwise over 1.5 min to tube B while bubbling HBS. The new solution was then incubated for 
20 min at room temperature. After incubating for 20 min at rm temp, 600 uL of each sample was 
added to 2 plates each containing ~6.8 million cells per 10 cm plates. VLPs were harvested 3 
days later. 
Harvesting and enriching for VLPs 
Spent supernatant containing secreted VLPs was collected in centrifuge tubes. Cells were 
pelleted away from the VLP supernatants by centrifuging the supernatant for 8 min at 1100 rpm. 
Ultracentrifuge tubes were loaded with 5 mL of NTE (100mM NaCL, 10mM Tris, 1 mM EDTA) 
containing 20% sucrose and then the VLP-containing-supernatant from the previous tubes were 
overlayered onto the sucrose layer. The samples were then ultracentrifuged using Optima XPN 
100 Ultracentrifuge (Beckman Coulter, Indianapolis, Indiana) at 100,000 g for 2 hrs at 10 oC. 
Supernatant was aspirated carefully leaving the VLP pellet. The pellet was washed with PBS. 
The media was aspirated and 100 uL of NTE was added to the pellet. The tubes were put on ice 
overnight. The next day, left-over VLPs were collected using another 200 uL NTE. Enriched 
VPLs were placed in 4 0C refrigerator until further use. 
Quantifying VLPs – Beta-lactamase Assay 
The VLPs were quantified using a Beta-lactamase assay. A working solution of 3 mL PBS and 3 
mL of cytobuster was prepared. The fluorocillin was then diluted to 5 uM using the 
PBS/cytobuster solution. To a 96 well, black, clear bottom plate 50 uL of 5uM fluorocillin was 
added to 12 wells. VLPs (20 uL) were then added in doublet to the prepared wells. Fluorescence 
spectra was taken after 20 min, 30 min, and 3.5 hrs incubation at room temperature. The data can 
be seen in Fig. 1. 
Isolation of Human Monocytes 
MojoSort kit (BioLegend, San Diego, California) was used to isolate human monocytes via 
negative selection (untouched human monocytes). Two blood samples were collected from 
anonymous donors. The fresh blood was diluted 1:2 with Hank’s Buffered Saline Solution 
(HBSS). Ficoll-Paque Plus, Amersham Biosciences, Amersham, United Kingdom was then 
underlaid with the diluted blood and centrifuged at 400 x g for 30 min at 200C. The buffy layer 
was collected and resuspended in HBSS and centrifuged again at 100 x g for 10 min at 200C. 
Cell concentration and viability was determined using a hemocytometer. This pellet was 
resuspended in 1X MojoSort Buffer. Human TruStain FcXTM was added to cells to block 
nonspecific antibody binding by incubating cells at rm temp for 10 min. Biotin-Antibody 
Cocktail was then added to cells and incubated on ice temp 15 min. The cells were resuspended 
and Streptavidin Nanobeads were added and incubated on ice for another 15 min. The cells were 
washed with MojoSortTM Buffer and centrifuged at 300 x g for 5 min. Supernatant was discarded 
and buffer was added. The cell suspension was placed on the magnet for 5 min. The non bound 
cells were collected. Cells were aliquoted into a 96 well plate at 370C with RPMI + 5% human 
serum with 50,000 cells per well.  
Human Monocyte stimulation with VLPS 
After cells adhered to the 96 well plate (2 days *can be done in 1 day) media was aspirated and 
replaced. VLPs and controls were added in triplicate to the plate (Table 3). The plates were then 
spinoculated for 1 hr at 2000 rpm at 4 0C. Plates were incubated at 37 0C. After 24, 48, and 72 











VLPs were produced in order to stimulate human monocytes. VLPs were produced from 
human embryonic kidney 293t cells transfected with combinations of DNA as shown in Table 1. 
The VLPs created were (1) VP40 + RIG-I-wildtype + GP, (2) VP40 + mutant-RIG-I + GP, (3) 
VP40 + RIG-I-wildtype + GPF88A, (4) VP40 + RIG-I-wildtype + GPF88A, (5) VP40 + 
flagVP40 + GP, and (6) VP40 + VSV-g (Table 1). A beta-lactamase assay was performed to 
quantify the relative amounts of each VLP since all VLP preparations were generated with a 
small amount of beta-lactamase-VP40 which is incorporated into each of the VLP preparations. 
(Figure 1). A sample of each VLP was incubated with fluorocillin for 20 min, 30 min and 3.5 
hrs. The average relative fluorescence unit after 3.5 hrs of incubation for sample  were (VP40 + 
VSV-g) 141,175, (VP40 + RIG-I-wildtype + GP) 124,111.5, (VP40 + mutant-RIG-I + GP) 
178,946, (VP40 + RIG-I-wildtype + GPF88A) 103,106.5, (VP40 + RIG-I-wildtype + GPF88A)  
107,979.5 and (VP40 + flagVP40 + GP) 346,878.5 respectively (Figure 1). Beta-lactamase is an 
enzyme that cleaves fluorocillin making it fluorescent. By measuring the fluorescence of 
fluorocillin, we were able to indirectly measure the relative amount of VLPs. The quantification 
of VLPs was used to apply the same relative amount of VLPs (beta-lactamase equivalents) to the 
human monocytes (table 3) in a stimulation assay. Two random samples of human monocytes 
were isolated using MojoSort kit.  
The six VLPs (VP40 + RIG-I-wildtype + GP, VP40 + mutant-RIG-I + GP, VP40 + RIG-I-
wildtype + GPF88A, VP40 + RIG-I-wildtype + GPF88A, VP40 + flagVP40 + GP, and VP40 + 
VSV-g) and 4 controls (background, negative control, LPS and VacV) were added in triplicate to 
the monocytes and incubated for 72 hrs with supernatant samples taken every 24 hrs. The 
supernatant was added to THP-1-Dual cells. THP-1-Dual cells contain the enzyme luciferase that 
is expressed in the presence of interferon. By monitoring the luminescence of luciferase, 
interferon can be proportionally measured. The luminescence of interferon was analyzed on the 
48 hrs sample (Figure 2). The average background luminescence was subtracted from the 
averages of all the others and graphed with standard deviation (Figure 2). The controls LPS 
(lipopolysaccharide) and VacV were both known stimulants of interferon (positive controls) 
while the negative control was not a stimulant of interferon. By measuring the level of interferon 
produced from each VLP and control, the efficacy of the VLPs to induce interferon can be 
assayed. The level of interferon was measured in monocyte #1 and #2 after being stimulated by 
VLPs and controls VP40 + RIG-I-wildtype + GP, VP40 + mutant-RIG-I + GP, VP40 + RIG-I-
wildtype + GPF88A, VP40 + RIG-I-wildtype + GPF88A, VP40 + flagVP40 + GP, VP40 + VSV-
g, negative control, LPS control, and VacV control were 1,255.7 and 763, 56.7 and 303.3, 37 and 
62, 0 and 93.7, 63.3 and 83.7, 1.3 and 167.3, 66 and 0, 121 and 170.7, 214.5 and 0 relative 




 Quantification using the beta-lactamase assay showed VLP production. It was predicted 
that the VLPs containing both GP and VP40 should produce the highest amount of VLPs. The 
EBOV protein GP is required for cellular entry while the EBOV protein VP40 is required for 
VLP budding from the cell (HEK 293t cells). This was tested by the positive control VP40 + GP 
+ flag-VP40 and the altered GP (GPF88A). The VLP with the highest production was VP40 + 
GP + flagVP40, which was more than 2 times greater than VP40 + RIG-I-wildtype + GP, VP40 
+ mutant-RIG-I + GP and VP40 + VSV-g and over 3 times greater than VP40 + RIG-I-wildtype 
+ GPF88A. Comparing the flagVP40 VLP to the other VLPs illustrates the importance of VP40 
in viral budding. Higher production of VLPs can be made with VP40. The VLPs that had the 
lowest production were VP40 + RIG-I-wt + GPF88A (Figure 1). The average amount of VLPs 
produced from VP40+ RIG-I-wt + GPF88A was 105,543 units of relative fluorescence. The 
mutated GP VLPs contained a nonfunctional attachment protein and illustrated a reduced amount 
of VLPs produced. In VP40 + RIG-I-wt + GP had 1.18 times greater VLP production than 
mutGP, while VP40 + mutRIG-I + GP had 1.22 times more VLP produced. The VSV-g VLP, 
which did not contain EBOV GP but a different attachment protein, produced 1.34 times more 
VLPs than mutGP (Figure 1). Although the VSV-g produced more VLPs than the EBOV GP, the 
EBOV GP is necessary for immune cell recognition of EBOV. 
 Human monocytes were isolated and stimulated with VP40 + RIG-I-wildtype + GP, 
VP40 + mutant-RIG-I + GP, VP40 + RIG-I-wildtype + GPF88A, VP40 + RIG-I-wildtype + 
GPF88A, VP40 + flagVP40 + GP, and VP40 + VSV-g as well as LPS and VacV. While LPS 
increased IFN in both monocyte harvested from two different individuals (1 and 2), VacV did 
not have significant IFN stimulation (Figure 2). The insignificant stimulation by the positive 
controls (LPS and VacV) may be due to the inability to work on the human monocytes prepared. 
Interferon produced by the monocytes were measured by luminescence. The highest production 
of interferon was seen in the monocytes stimulated by VP40 + RIG-I-wt + GP. The RIG-I 
adjuvant’s effectiveness can be seen when comparing VP40 + RIG-I-wt + GP with VP40 + 
mutRIG-I + GP. In monocyte #1, VLP VP40 + RIG-I-wildtype + GP had a 22-fold greater 
production of IFN than VLP VP40 + mutant-RIG-I + GP; while in monocyte #2, VLP VP40 + 
RIG-I-wildtype + GP had a 2.5-fold increase in IFN production. Both monocyte #1 and #2 
present data that demonstrates RIG-I-wt effectiveness at increasing IFN production. The lowest 
production of interferon was seen in the monocytes stimulated by the negative control and VLPs 
VP40 + RIG-I-wt + GPF88A. With the GPF88A mutant glycoprotein, entry into monocytes will 
be abrogated. The RIG-I pathway of inducing IFN production is an intracellular process. Without 
GP-mediated entry into the cell, the RIG-I has no access to the cytoplasm to stimulate IFN 
production. This further emphasizes the importance of GP in the VLP. The samples VP40 + 
mutRIG-I + GP, VP40 + VSV-g, and LPS all had similar levels of interferon production (Figure 
2). These similar levels illustrate that VLPs without the RIG-I adjuvant and functional GP 
produce similar effects as the known IFN stimulator LPS. LPS and VacV stimulate IFN through 
inflammation, while the PRR, RIG-I, is directly in the pathway for IFN stimulation, which 
apparently makes it more effective at producing IFN in monocytes. The adjuvant, RIG-I, showed 
better stimulation of human monocytes. To further illustrate the effectiveness of VLPs using 
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Figures 
   
Figure 1. VLP quantification using Beta-lactamase assay and relative fluorescence taken 20 
minutes, 30 minutes, and 3.5 hours after incubation with fluorocillin. 
 
  
Figure 2. Interferon quantification by luminescence reading of VLP stimulated human 
monocytes of two individuals (blue and orange). 
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